PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26324362-10	2015	Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XELOX efficacy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS HR was 2.45 (95% CI, 1.55 to 3.86; P < .001), and OS HR was 2.75 (95% CI, 1.65 to 4.59; P < .001).	XELOX	78-83	dihydropyrimidine dehydrogenase	Homo sapiens	24-55	
31124962-8	2019	According to the disease stage, he started an adjuvant therapy with XELOX using capecitabine at 50% of total dose, because of his DPYD IVS14+1G>A variant, detected before the treatment.	XELOX	68-73	dihydropyrimidine dehydrogenase	Homo sapiens	130-134	
26324362-10	2015	Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XELOX efficacy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS HR was 2.45 (95% CI, 1.55 to 3.86; P < .001), and OS HR was 2.75 (95% CI, 1.65 to 4.59; P < .001).	XELOX	101-106	dihydropyrimidine dehydrogenase	Homo sapiens	24-55	
26324362-10	2015	Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XELOX efficacy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS HR was 2.45 (95% CI, 1.55 to 3.86; P < .001), and OS HR was 2.75 (95% CI, 1.65 to 4.59; P < .001).	XELOX	101-106	dihydropyrimidine dehydrogenase	Homo sapiens	134-165	
26324362-14	2015	Tumoral dihydropyrimidine dehydrogenase expression is a promising predictive, and potentially, highly clinically relevant, biomarker for XELOX efficacy requiring further prospective evaluation.	XELOX	137-142	dihydropyrimidine dehydrogenase	Homo sapiens	8-39	
16292536-0	2006	Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.	XELOX	51-56	dihydropyrimidine dehydrogenase	Homo sapiens	98-130